azacitidine has been researched along with incb-018424 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Cinalli, T; Colaluca, K; Duong, HK; Rogers, HJ; Saunthararajah, Y; Sekeres, MA; Stein, BL; Tabarroki, A; Tiu, RV; Visconte, V | 1 |
| Galli, S; Harrison, CN; Keohane, C; McLornan, DP; Mwirigi, A; Radia, DH; Raj, K | 1 |
| Mascarenhas, J | 1 |
| Abdel-Wahab, O; Ahn, J; Armstrong, SA; Chiosis, G; Chung, YR; Dogan, A; Hricik, T; Intlekofer, A; Levine, RL; Lipson, D; Manshouri, T; McKenney, AS; Miller, VA; Nahas, M; Otto, GA; Pandey, S; Park, CY; Rampal, R; Rapaport, F; Stephens, PJ; van den Brink, MR; Verstovsek, S; Wang, K; Yelensky, R | 1 |
| Diamantopoulos, PT; Giannakopoulou, N; Hatzidavid, S; Viniou, NA | 1 |
| Bobin, A; Cayssials E, E; Chomel, JC; Desmier, D; Gallego-Hernanz, P; Gardeney, H; Maillard, N; Moya, N; Systchenko, T; Torregrosa, J; Vonfeld, M | 1 |
1 review(s) available for azacitidine and incb-018424
| Article | Year |
|---|---|
Rationale for combination therapy in myelofibrosis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Clinical Trials as Topic; Decitabine; Drug Therapy, Combination; Gene Expression; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Hydroxamic Acids; Indoles; Janus Kinase 2; Mutation; Nitriles; Panobinostat; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Recombinant Proteins; Serum Amyloid P-Component | 2014 |
6 other study(ies) available for azacitidine and incb-018424
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Hematologic Neoplasms; Humans; Male; Myeloproliferative Disorders; Nitriles; Pyrazoles; Pyrimidines | 2014 |
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.
Topics: Animals; Azacitidine; Benzodioxoles; Blotting, Western; Colony-Forming Units Assay; Decitabine; Exome; Flow Cytometry; Hematologic Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Purines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53 | 2014 |
Post-Myelofibrosis Acute Myeloid Leukemia Effectively Treated with a Combination of Ruxolitinib and 5-Azacytidine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Topics: Aged; Aged, 80 and over; Azacitidine; Blast Crisis; Humans; Myeloproliferative Disorders; Quality of Life; Treatment Outcome | 2023 |